
Overview
Syvento is a biotechnology company that offers development and formulation services for lipid-based nanocarriers and LNP technology. It specializes in creating lipid-based formulations for pharmaceutical products, including RNA-based drug products. The company provides solutions for encapsulating and delivering therapeutic molecules such as small molecules, RNA, DNA, and proteins.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $0 |
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 91 days late). 1 of 6 audited by a statutory auditor.
- 202510/07/2026
- 202408/07/2025
- 202312/07/2024
- 202206/07/2023
- 202114/10/2022
- 202015/10/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

SyVento BioTech at Cell & Gene Therapy International Europe 2026: From Innovation to GMP Manufacturing
SyVento BioTech will join Cell & Gene Therapy International Europe 2026, taking place on 3–5 November at Hotel Palace Berlin, Germany. The event brings together global biotechnology and pharmaceutical leaders to address one of the industry’s most pressing challenges: translating advanced therapeutic innovations into scalable, commercially viable manufacturing processes. As cell and gene therapies advance […]

SyVento BioTech at TIDES Europe 2026: Advancing RNA Therapeutics from Development to GMP Manufacturing
SyVento BioTech will attend TIDES Europe 2026, taking place on 3–5 November at RAI Amsterdam, the Netherlands. Our representatives, Eliza Milewicz and Andreas Wendt, will meet with biotechnology and pharmaceutical companies seeking advanced RNA development, LNP delivery and GMP manufacturing solutions. TIDES Europe brings together global leaders in oligonucleotide, peptide and RNA therapeutics to address […]

Announcement of the merger plan of SyVento sp. z o.o. and ISONO Cosmetics sp. z o.o.

Advancing Gene Therapy: SyVento BioTech at ESGCT 2026 in Hamburg
The future of gene therapy depends on more than the ability to develop groundbreaking treatments. It depends on delivering them effectively, manufacturing them reliably and making them ready for clinical development. SyVento BioTech participated in the 33rd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), held on 27–30 October 2026 at […]

From Rare Disease Innovation to Manufacturing Reality: SyVento BioTech at World Orphan Drug Congress Europe 2026
Breakthrough science is transforming the future of rare disease treatment. But bringing innovative therapies to patients requires more than scientific discovery — it demands the right development and manufacturing strategy. SyVento BioTech participated in World Orphan Drug Congress Europe 2026, held on 27–28 October at RAI Amsterdam, joining the international rare disease community to explore […]

Beyond Vaccine Innovation: SyVento BioTech at World Vaccine Congress Europe 2026
The next generation of vaccines will be defined not only by scientific breakthroughs, but by how effectively those breakthroughs can be translated into scalable, reliable manufacturing. SyVento BioTech joined World Vaccine Congress Europe 2026, held on 19–21 October at RAI Amsterdam, one of the industry’s leading gatherings connecting vaccine developers, biotechnology companies, pharmaceutical manufacturers and […]
Industry
- Manufacture of vegetable and animal oils and fats (10.4)
- Manufacture of other food products (10.8)
Offer
- Lipid formulations
- mRNA synthesis
- Drug delivery systems
- Drug development
- Fill and finish services
Websites
- syvento.comSyVento BioTech: Extensive Expertise in mRNA Formulations & LNP TechnologyWordPress 7.1Google Tag ManagerYoast SEOWWPMLLLiteSpeed
Public procurement
No recorded participation in tenders.
The company is the contractor in one public sector contract, worth USD 18.10k.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Aug 6, 2026 | Provision of encapsulation services | $18,098 | Instytut Chemii Bioorganicznej Polskiej Akademii Nauk |
Trademarks
The company holds 2 active trademarks registered with the Polish Patent Office. The first mark was filed in 2020.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| COVIDEZ (word) | Z.524981 | 5 | Protected | Feb 22, 2031 | |
| COVIREX (word) | Z.511485 | 5 | Protected | Mar 13, 2030 |
| Mark | Protected until | |
|---|---|---|
| COVIDEZ (word) | Feb 22, 2031 | |
| COVIREX (word) | Mar 13, 2030 |
Job offers
The company lists 3 job openings on its own careers page: syvento.com/careers.
Authorized Representatives
Manner of representation
In the case of a one-person management board, declarations of will on behalf of the company are made and documents are signed by the member of the management board. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations of will and sign documents on behalf of the company.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Ms Galleon Gmbh | 30,000 | $486,223.66 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Capital group
The company belongs to the MS Galleon GmbH (Austria) group, which is its direct owner. The group has 15 companies, 5 of them abroad.
| Name | Country |
|---|---|
| Barlinek | |
| Barlinek Inwestycje | |
| Cersanit | |
| Ekovoltis | |
| FTF Columbus |
Bank accounts
Registered as a VAT taxpayer on 2017-05-09.
27 1090 1652 0000 0001 6790 9183
05 1090 1652 0000 0001 3419 3058
21 1090 1652 0000 0001 3419 3061
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 10.2MPLN 10,211,093 |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Mar 17, 2021 | Transformation registered |
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| JJP Biologics sp. z o.o. | $4,998,735.31 | jjpbiologics.com | ||
| Lipid Systems sp. z o.o. | $4,497,777.98 | lipidsystems.pl | ||
| Biotechna S.A. | $2,472,888.07 | bsbiotechna.com | ||
| Captor Therapeutics S.A. | $2,286,539.43 | captortherapeutics.pl | ||
| Molecure S.A. | $1,889,300.60 | molecure.com | ||
| Aslab Science P.S.A. | $1,504,132.17 | aslabsci.com | ||
| Pikralida sp. z o.o. | $1,151,165.63 | pikralida.eu | ||
| Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o. | $969,037.30 | kmptm.pl | ||
| Nanogroup S.A. | $843,099.47 | nanogroup.eu | ||
| Precisionlife Poland sp. z o.o. | $617,020.34 | precisionlife.com |
Change history
| Date | Event | |
|---|---|---|
| 2023-06-05 | Address change (Ul. Chemików 1, 32-600, Oświęcim → Ul. Za Górą 19, 32-050, Skawina) | |
| 2021-07-15 | Share capital increase (1,500,000.00 PLN → 1,800,000.00 PLN) | |
| 2021-03-01 | Entered in the register |
FAQ
Last updated: 2026-10-07